Artivion Earnings Call Transcripts
Fiscal Year 2026
-
The company has built a leading aortic arch portfolio through acquisitions, targeting a $400 million U.S. market and $2 billion globally. AMDS and NEXUS launches are key near-term drivers, with PMA approvals and global expansion expected to accelerate growth.
-
Q1 2026 saw 12% revenue and 26% adjusted EBITDA growth, led by On-X and stent grafts, but international softness and AMDS set sales timing prompted a guidance reduction. Endospan acquisition and NEXUS launch are set to expand the aortic arch portfolio and drive future growth.
-
AMDS is driving accelerated stent graft growth, with 2026 focused on expanding account penetration and implant-driven revenue. On-X benefits from strong clinical data and market expansion, while NEXUS approval and acquisition are anticipated. Mature products remain steady, and new launches are set to boost margins and operating leverage.
Fiscal Year 2025
-
Delivered 13% revenue and 26% adjusted EBITDA growth in 2025, with strong Q4 results led by stent grafts and On-X. 2026 guidance calls for 10%-14% revenue growth and 18%-22% adjusted EBITDA growth, supported by new product launches, clinical data, and ongoing margin expansion.
-
Aortic-focused innovation and strategic acquisitions have built a robust product pipeline, driving double-digit revenue and margin expansion. AMDS and On-X are fueling growth, with new clinical data and reimbursement tailwinds, while operational and financial discipline support sustained performance.
-
Q3 2025 saw 16% revenue and 39% adjusted EBITDA growth, led by strong stent graft and On-X valve performance. Guidance for 2025 was raised, with double-digit growth expected to continue, supported by new product launches, clinical data, and expanded manufacturing capacity.
-
Management outlined a strategy focused on aorta-related products, double-digit growth, and expanding EBITDA margins, driven by a robust PMA-protected pipeline. New product launches, especially in the U.S., are expected to accelerate growth and profitability, with international sales remaining strong.
-
Strong double-digit growth is driven by On-X and stent businesses, supported by robust clinical data and a de-risked pipeline targeting $1 billion in new opportunities. Financial performance is improving with expanding margins, positive cash flow, and a focus on deleveraging and strategic acquisitions.
-
Q2 2025 saw 14% revenue and 33% adjusted EBITDA growth, driven by strong On-X and AMDS performance, improved margins, and significant debt reduction. Full-year guidance was raised, with accelerating growth expected in H2 and robust pipeline progress.
-
Focused on aortic solutions, the company is launching high-margin products like AMDS and NEXUS, driving sequential growth and expanding global reach. Clinical data supports strong adoption, while operational leverage and reduced debt position the business for durable EBITDA and free cash flow growth.
-
Q1 2025 results exceeded expectations with 4% revenue growth and strong recovery from a cyber incident. Stent Graft, Onyx, and BioGlue segments grew, while tissue processing is rebounding. Guidance for 2025 was raised, with AMDS and Nexus launches driving future growth.
-
Operations have stabilized post-cyber breach, with some Q1 revenue deferred. The company is launching AMDS, expanding On-X, and expects double-digit growth with EBITDA margin expansion. Tariff and FX risks are minimal, and a strong pipeline supports long-term growth.
Fiscal Year 2024
-
Delivered 10% constant currency revenue growth and 32% adjusted EBITDA growth in 2024, overcoming a cyber incident that temporarily impacted Q4. 2025 guidance calls for 10%-14% revenue growth, margin expansion, and strong product momentum, especially for AMDS and On-X.
-
Double-digit growth is projected through 2025, driven by innovative products like AMDS, which shows strong clinical and commercial promise. U.S. and international expansion, including BioGlue in China, and a focus on margin improvement and strategic debt management, support a positive outlook.
-
Q3 2024 delivered 10% revenue and 28% adjusted EBITDA growth, with strong product and geographic performance. Regulatory milestones, including BioGlue approval in China and AMDS PMA progress, support confidence in sustained double-digit growth and margin expansion.
-
Aortic-focused medtech firm projects double-digit revenue and strong EBITDA growth, driven by differentiated heart valves, stent grafts, and a robust innovation pipeline. Operational leverage, expanding international markets, and a healthy balance sheet support sustained performance.
-
Q2 2024 saw 10% revenue growth and 35% adjusted EBITDA growth year-over-year, led by strong performance in On-X, stent grafts, and BioGlue. Guidance for 2024 was raised, with continued expansion in international markets and improved leverage.